about
Anemia under androgen deprivation: influence of flutamide, cyproteroneacetate and orchiectomy on the erythropoietin system[Metastatic castration-resistant prostate cancer : Clinical data, new treatment options and therapy monitoring].[Transcriptome expression analyses of pulmonary renal cell carcinoma metastases]Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient.Identification of high-risk patients with clear cell renal cell carcinoma based on interphase-FISH.Risk factors for incidental prostate cancer-who should not undergo vaporization of the prostate for benign prostate hyperplasia?Supraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway.Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines.180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial--the GOLIATH study.Advances in renal cell carcinoma treatment.FISH analysis of washing urine from the upper urinary tract for the detection of urothelial cancers.A European multicenter randomized noninferiority trial comparing 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-month results of the GOLIATH study.A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study.The contemporary concept of significant versus insignificant prostate cancer.Relationship between expression of KAI1 metastasis suppressor gene, mRNA levels and p53 in human bladder and prostate cancer cell lines.Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells.MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases.Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians.Assessment of PI-RADS v2 for the Detection of Prostate Cancer.Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells.High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey.Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo.An alternatively spliced KAI1 mRNA is expressed at low levels in human bladder cancers and bladder cancer cell lines and is not associated with invasive behaviour.[Diagnosis and treatment of retroperitoneal abscesses].KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells.Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles.Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy--A Prospective Multicenter Study.Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.Gigantic Suprapubic Lymphedema: A Case Study.Placental Schistosoma haematobium infection in a German returnee from Malawi.Prevalence and Management of Lower Urinary Tract Symptoms Related to Benign Prostatic Obstruction in a Contemporary Series of Renal Transplant Recipients.High-grade Carcinoma of the Proximal Ureter With Negative Nephroureteroscopy Detected by a Positive FISH Test: A Rare Case Report.Whole-body MRI in follow-up of patients with renal cell carcinoma.Anticholinergic effects of cis- and trans-isomers of two metabolites of propiverine.Establishment of a multicolour fluorescence in situ hybridisation-based assay for subtyping of renal cell tumours.Evidence from the 'PROspective MulticEnTer RadIcal Cystectomy Series 2011 (PROMETRICS 2011)' study: how are preoperative patient characteristics associated with urinary diversion type after radical cystectomy for bladder cancer?
P50
Q28567715-D761C688-0A58-4A25-B684-62AE9F9F98F8Q31114538-729837FC-B471-4067-A0EB-CEDCC78C10AAQ33290318-E0857355-E86A-49E9-AC31-684731BB7699Q33434591-2ADC2066-ECA0-4698-A3F5-5E07A9192F37Q33613566-5504F7C9-F73A-4D4F-BE84-1903332D10C0Q33817164-0063404F-5326-4498-96D7-5479FD1A9D52Q34227242-637F52C5-F82A-4128-88FA-938D062D08FEQ34359505-81DB4FA4-6B0F-4A7B-9107-5F8BCBAEA3EEQ35065643-2AC513AA-E2B7-42C4-861E-B72B27D8A8A0Q35076407-58C93A62-0084-4645-97CB-1530F0793774Q35154327-158D90E5-A666-42D5-8C21-A7698BEC8DBDQ35251884-A4CA1F31-EC8C-4837-B35C-15F1F00F3341Q35748289-B12B61C7-6031-434A-8945-CDC92385E156Q37878140-626F97BD-9EA6-4543-9415-18BC5764BBC5Q38359952-F6207D51-2812-4CA3-9D30-A4D724BCF23BQ38457425-0CF96E42-7F68-4DD4-905F-7B3015DAA819Q38760440-FC864E65-7955-405C-A498-BC39F28B052EQ38958176-4846D6B5-C7BE-4537-86A4-5E5013A8B7C3Q39062231-0A293574-FAE4-4814-A588-25036DE5CA01Q39107888-EFE7C3FF-4048-4A81-AB62-CD9F1A9CAA6EQ39265374-0FBF3162-8FE6-41C8-9383-A5AE668E1581Q39925072-E7ED6EC9-15F1-4CAE-A4F4-D0C8EC30750EQ39946690-C31E6FED-DE23-460D-8774-C1B035B9C572Q39974010-EA1CD59A-F390-49E8-B2CD-0166A2CD5EF6Q39990295-577D193D-0F85-4782-81C5-5FCB5324F9F9Q40056564-68DC6964-6A2B-41A8-AF0A-97453362EE7CQ40104412-553CE17F-98E6-4747-BBD0-64DE3A3F20FCQ40484635-F707B81B-83BB-434B-9811-A8FEADC9EEF2Q40552177-E6808C5B-E93B-4D26-BDE0-55B9E02C86F3Q40588270-F967D7B2-95F0-4E80-89C1-E60AA9B5A038Q40772011-C1A04712-F9BA-4D76-98B2-82DF734D0D4EQ40875500-289ED2DC-C589-4C34-A1C7-1DFCA6BE6B3AQ41120414-216E6970-8DF0-4C74-BF08-0C2DAF07CE82Q41734142-01BD836A-C288-41C3-BB34-7FD108EBCF36Q41908064-E6C9F97E-9B56-4CCD-A13D-DC107C149137Q42142369-41525C19-64AB-42BA-B347-A6730F9A089FQ43080277-A99232C7-0266-48BC-93E1-013CCE4A267DQ43150698-B5025F11-70B4-4327-A2CB-C728C519802FQ43428322-169D7DDE-7939-4B30-8786-74F058797BC7Q43900072-8FA46079-D65E-4863-B3B7-A7BCCA01FA36
P50
description
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Marc-Oliver Grimm
@ast
Marc-Oliver Grimm
@en
Marc-Oliver Grimm
@es
Marc-Oliver Grimm
@nl
Marc-Oliver Grimm
@sl
type
label
Marc-Oliver Grimm
@ast
Marc-Oliver Grimm
@en
Marc-Oliver Grimm
@es
Marc-Oliver Grimm
@nl
Marc-Oliver Grimm
@sl
prefLabel
Marc-Oliver Grimm
@ast
Marc-Oliver Grimm
@en
Marc-Oliver Grimm
@es
Marc-Oliver Grimm
@nl
Marc-Oliver Grimm
@sl
P214
P106
P1153
7103386719
P21
P214
P31
P496
0000-0003-3084-8654
P734
P7859
viaf-20415415